J. Molner has successfully presented its first complete submission to the U.S Food and Drug Administration. Molner’s generic topical drug, MOL-004, is subject to FDA review and may be eligible for approval in the first half of 2024.
J. Molner has successfully presented its first complete submission to the U.S Food and Drug Administration. Molner’s generic topical drug, MOL-004, is subject to FDA review and may be eligible for approval in the first half of 2024.